[{"orgOrder":0,"company":"TaiRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Foslinanib","moa":"angiogenesis inhibitors; phosphoro-derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"TaiRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TaiRx \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TaiRx \/ Undisclosed"},{"orgOrder":0,"company":"TaiRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Foslinanib","moa":"angiogenesis inhibitors; phosphoro-derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"TaiRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TaiRx \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TaiRx \/ Undisclosed"},{"orgOrder":0,"company":"TaiRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Foslinanib","moa":"angiogenesis inhibitors; phosphoro-derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"TaiRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TaiRx \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TaiRx \/ Undisclosed"},{"orgOrder":0,"company":"National Health Research Institutes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"DBPR115","moa":"Cancer cell membrane protein-phosphatidyl serine","graph1":"Oncology","graph2":"Phase I","graph3":"National Health Research Institutes","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Health Research Institutes \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"National Health Research Institutes \/ Undisclosed"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"Casein kinase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"Casein kinase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"Casein kinase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"GenomeFrontier Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GF-CART01","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"GenomeFrontier Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenomeFrontier Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GenomeFrontier Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eden Biologics","sponsor":"National Taiwan University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CD19-mbIL15 CAR-T Cell","moa":"CD19 \/ IL-15","graph1":"Oncology","graph2":"Phase I","graph3":"Eden Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eden Biologics \/ National Taiwan University Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Eden Biologics \/ National Taiwan University Hospital"},{"orgOrder":0,"company":"Acepodia","sponsor":"Digital Mobile Venture","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2023","type":"Series D Financing","leadProduct":"ACE1831","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Acepodia \/ Digital Mobile Venture","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Digital Mobile Venture"},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"JHL1101","moa":"CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Eden Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eden Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eden Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Acepodia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acepodia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Undisclosed"},{"orgOrder":0,"company":"Acepodia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acepodia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Undisclosed"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"OBI-3424","moa":"||DNA","graph1":"Oncology","graph2":"Phase I","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBI Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"OBI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEngine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaEngine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEngine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PharmaEngine \/ Undisclosed"},{"orgOrder":0,"company":"Acepodia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ACE1702","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acepodia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Undisclosed"},{"orgOrder":0,"company":"Acepodia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ACE1702","moa":"||Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acepodia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Undisclosed"},{"orgOrder":0,"company":"Acepodia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"ACE1702","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acepodia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Undisclosed"},{"orgOrder":0,"company":"Acepodia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ACE1702","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acepodia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Undisclosed"},{"orgOrder":0,"company":"Acepodia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ACE1702","moa":"||Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acepodia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Undisclosed"},{"orgOrder":0,"company":"Acepodia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ACE1702","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acepodia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Undisclosed"},{"orgOrder":0,"company":"Acepodia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"ACE1702","moa":"||Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acepodia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Undisclosed"},{"orgOrder":0,"company":"Acepodia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"ACE1702","moa":"||Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acepodia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Undisclosed"},{"orgOrder":0,"company":"Acepodia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ACE1702","moa":"||Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acepodia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Undisclosed"},{"orgOrder":0,"company":"Acepodia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ACE1702","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acepodia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Undisclosed"},{"orgOrder":0,"company":"Acepodia","sponsor":"Ridgeback Capital Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2021","type":"Series B Financing","leadProduct":"ACE1702","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Acepodia \/ Ridgeback Capital Investments","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Ridgeback Capital Investments"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"OBI-833","moa":"Globo H","graph1":"Oncology","graph2":"Phase I","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBI Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"OBI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"NatureWise Biotech & Medicals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"NBM-BMX","moa":"HDAC8","graph1":"Oncology","graph2":"Phase I","graph3":"NatureWise Biotech & Medicals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"NatureWise Biotech & Medicals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NatureWise Biotech & Medicals \/ Undisclosed"},{"orgOrder":0,"company":"NatureWise Biotech & Medicals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"NBM-BMX","moa":"HDAC8","graph1":"Oncology","graph2":"Phase I","graph3":"NatureWise Biotech & Medicals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"NatureWise Biotech & Medicals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NatureWise Biotech & Medicals \/ Undisclosed"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Tri-Service General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"UB-921","moa":"IGF-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United BioPharma \/ Tri-Service General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"United BioPharma \/ Tri-Service General Hospital"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Efficient Pharma Management","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"P1101","moa":"Interferon alpha\/beta receptor","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ Efficient Pharma Management","highestDevelopmentStatusID":"6","companyTruncated":"PharmaEssentia \/ Efficient Pharma Management"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CX-5461","moa":"PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Senhwa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pidnarulex","moa":"||PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pidnarulex","moa":"||PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Peter MacCallum Cancer Centre","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pidnarulex","moa":"||PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Peter MacCallum Cancer Centre","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Peter MacCallum Cancer Centre"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pidnarulex","moa":"PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Senhwa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pidnarulex","moa":"PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Senhwa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pidnarulex","moa":"PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Senhwa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pidnarulex","moa":"PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Senhwa Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEngine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"PEP08","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaEngine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEngine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PharmaEngine \/ Undisclosed"},{"orgOrder":0,"company":"Holy Stone Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"CA102N","moa":"Prostaglandin G\/H synthase 2 (COX-2)","graph1":"Oncology","graph2":"Phase I","graph3":"Holy Stone Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Holy Stone Healthcare \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Holy Stone Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Primo Biotechnology","sponsor":"Kaohsiung Chang Gung Memorial Hospital,Taiwan","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"18-F PSMA","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Primo Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Primo Biotechnology \/ Kaohsiung Chang Gung Memorial Hospital,Taiwan","highestDevelopmentStatusID":"6","companyTruncated":"Primo Biotechnology \/ Kaohsiung Chang Gung Memorial Hospital,Taiwan"},{"orgOrder":0,"company":"EirGenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"EirGenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EirGenix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"EirGenix \/ Undisclosed"},{"orgOrder":0,"company":"EirGenix","sponsor":"Sacura GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"EirGenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EirGenix \/ Sacura GmbH","highestDevelopmentStatusID":"6","companyTruncated":"EirGenix \/ Sacura GmbH"},{"orgOrder":0,"company":"Innopharmax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1 | DNA polymerase (alpha\/delta\/epsilon)","graph1":"Oncology","graph2":"Phase I","graph3":"Innopharmax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innopharmax \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innopharmax \/ Undisclosed"},{"orgOrder":0,"company":"Innopharmax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1 | DNA polymerase (alpha\/delta\/epsilon)","graph1":"Oncology","graph2":"Phase I","graph3":"Innopharmax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innopharmax \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innopharmax \/ Undisclosed"},{"orgOrder":0,"company":"UWELL Biopharma","sponsor":"Tri-Service General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Welgenaleucel","moa":"T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"UWELL Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UWELL Biopharma \/ Tri-Service General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"UWELL Biopharma \/ Tri-Service General Hospital"},{"orgOrder":0,"company":"PharmaEngine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"PEP02","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaEngine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEngine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PharmaEngine \/ Undisclosed"},{"orgOrder":0,"company":"GlycoNex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"GNX102","moa":"Tumor-associated glycan antigen (TAGA)","graph1":"Oncology","graph2":"Phase I","graph3":"GlycoNex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GlycoNex \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GlycoNex \/ Undisclosed"},{"orgOrder":0,"company":"AP Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AP505","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AP Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AP Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Standard Chem. & Pharm. Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"DCBCI0901","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Standard Chem. & Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Standard Chem. & Pharm. Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Standard Chem. & Pharm. Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"LaunXP Biomedical","sponsor":"Efficient Pharma Management","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LXP1788","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"LaunXP Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LaunXP Biomedical \/ Efficient Pharma Management","highestDevelopmentStatusID":"6","companyTruncated":"LaunXP Biomedical \/ Efficient Pharma Management"},{"orgOrder":0,"company":"MegaPro Biomedical","sponsor":"National Taiwan University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MPB-2043","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MegaPro Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MegaPro Biomedical \/ National Taiwan University Hospital","highestDevelopmentStatusID":"6","companyTruncated":"MegaPro Biomedical \/ National Taiwan University Hospital"},{"orgOrder":0,"company":"Medigen Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Natural Killer Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Medigen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigen Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Medigen Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"OB318","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oneness Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oneness Biotech \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEngine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PEP07","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaEngine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PharmaEngine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PharmaEngine \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEngine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"PEP07","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaEngine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PharmaEngine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PharmaEngine \/ Undisclosed"},{"orgOrder":0,"company":"SynCore Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"SCB01A","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SynCore Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SynCore Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SynCore Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"SynCore Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"SCB01A","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SynCore Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SynCore Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SynCore Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Taivex Therapeutics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"T-1101 Tosylate","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Taivex Therapeutics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Taivex Therapeutics Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taivex Therapeutics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Taivex Therapeutics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"T-1101 Tosylate","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Taivex Therapeutics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Taivex Therapeutics Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taivex Therapeutics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Taivex Therapeutics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"T-1101 Tosylate","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Taivex Therapeutics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Taivex Therapeutics Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taivex Therapeutics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Taivex Therapeutics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"T-1201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Taivex Therapeutics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Taivex Therapeutics Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taivex Therapeutics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Taivex Therapeutics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"T-1301","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Taivex Therapeutics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Taivex Therapeutics Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taivex Therapeutics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"TaiRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TRX-920","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TaiRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TaiRx \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TaiRx \/ Undisclosed"},{"orgOrder":0,"company":"AP Biosciences","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AP601","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AP Biosciences \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"AP Biosciences \/ Avance Clinical"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
